trial

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

NCTId NCT03713658
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 34 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Primary completion 2019-12-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
34 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Sequential
Masking
None
Start
2018-10-18
Primary completion
2019-12-02
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
RisperidonePaliperidone

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

3 total
Kigali, RwandaMusanze District, RwandaNgoma District, Rwanda

Facts & assertions

4 sourced
Enrollment
34
Phase
PHASE4
Primary Completion Date
2019-12-02
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
Paliperidone
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication